site without changing your settings, you are agreeing to accept all cookies on the site.
Personal Protective Equipment (PPE) decontamination for reuse
Battelle's response to the novel coronavirus (SARS-CoV-2)
As new drug formulations demand new answers, Battelle is developing novel solutions to these challenges.
Working with pharmaceutical and government clients and researchers to deliver solutions that address emerging health threats, including coronavirus.
Modeling the movement of PFAS plumes in groundwater
Battelle's ThreatSEQ solution is a web-based analytical software tool and service for rapid screening of DNA sequences submitted for gene synthesis.
When you are looking to select or develop the optimal delivery mechanism for a new drug or therapy and accelerate their path through the regulatory process, think Battelle.
Battelle’s Biomedical Research Center (BRC) contains the largest privately owned Biosafety Level 3 (BSL-3) facility in the United States.
From the field to the lab, Battelle is leading the way in development of new solutions for emerging environmental problems—like per- and polyfluoroalkyl substances (PFAS).
Battelle offers valuable analysis and assessment for vaccines, prophylactic compounds and therapeutics for a wide array of infectious diseases, medical countermeasures and biological threats.
We provide fast, economical and nondestructive authentication of integrated circuits and microchips from trusted and untrusted sources.
VIDEO: Battelle is Advancing Neurotechnology Capabilities
Battelle designed and built the CCDS Critical Care Decontamination System™ for decontaminating single-use disposable N95 PPE, allowing for reuse.
The last will and testament of Gordon Battelle (and a hefty gift of more than $1 million) founded the Battelle Memorial Institute in the early 1920s. But without his mother, we might not be here to tell the tale.
Battelle is working with commercial, academic and government entities to support the global efforts to understand, test and treat the virus.